In this section

Research

Biological systems - including the simplest cells - exhibit a broad range of functions to thrive in their environment. Research in the Imperial College Centre for Synthetic Biology is focused on the possibility of engineering the underlying biochemical processes to solve many of the challenges facing society, from healthcare to sustainable energy. In particular, we model, analyse, design and build biological and biochemical systems in living cells and/or in cell extracts, both exploring and enhancing the engineering potential of biology.

As part of our research we develop novel methods to accelerate the celebrated Design-Build-Test-Learn synthetic biology cycle. As such research in the Centre for Synthetic Biology highly multi- and interdisciplinary covering computational modelling and machine learning approaches; automated platform development and genetic circuit engineering ; multi-cellular and multi-organismal interactions, including gene drive and genome engineering; metabolic engineering; in vitro/cell-free synthetic biology; engineered phages and directed evolution; and biomimetics, biomaterials and biological engineering.

Publications

Citation

BibTex format

@article{Klymenko:2016:10.1002/aic.15388,
author = {Klymenko, O and Royle, K and Polizzi, KM and Shah, N and Kontoravdi, C},
doi = {10.1002/aic.15388},
journal = {AICHE Journal},
pages = {2959--2973},
title = {Designing an Artificial Golgi Reactor to achieve targeted glycosylation of monoclonal antibodies},
url = {http://dx.doi.org/10.1002/aic.15388},
volume = {62},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The therapeutic efficacy of monoclonal antibodies (mAbs) is dependent upon their glycosylationpatterns. As the largest group of currently approved biopharmaceuticals, the microheterogeneity inmAb oligosaccharide profiles deriving from mammalian cell production is a challenge to thebiopharmaceutical industry. Disengaging the glycosylation process from the cell may offer significantenhancement of product quality and allow better control and reproducibility in line with the Quality byDesign paradigm. Three potential designs of an Artificial Golgi reactor implementing targeted sequentialglycosylation of mAbs are proposed including a (i) microcapillary film reactor, (ii) packed bed reactorwith non-porous pellets, and (iii) packed bed reactor with porous pellets. Detailed mathematical modelsare developed to predict their performance for a range of design and operational parameters. While allthree reactor designs can achieve desired conversion levels, the choice of a particular one depends onthe required throughput and the associated cost of enzymes and co-substrates.
AU  - Klymenko,O
AU  - Royle,K
AU  - Polizzi,KM
AU  - Shah,N
AU  - Kontoravdi,C
DO  - 10.1002/aic.15388
EP  - 2973
PY  - 2016///
SN  - 0001-1541
SP  - 2959
TI  - Designing an Artificial Golgi Reactor to achieve targeted glycosylation of monoclonal antibodies
T2  - AICHE Journal
UR  - http://dx.doi.org/10.1002/aic.15388
UR  - http://hdl.handle.net/10044/1/34029
VL  - 62
ER  -